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ORIGINAL ARTICLE
BMP signaling modulation attenuates cerebral arteriovenous
malformation formation in a vertebrate model
Brian P Walcott
1,2
Cerebral arteriovenous malformations (AVMs) are vascular anomalies that carry a high risk of stroke and death. To test potential
AVM therapies, a reverse genetics approach was used to model AVMs in zebraﬁsh. Antisense morpholino oligonucleotides were
used to knockdown activin receptor-like kinase I (alk1), which encodes a transforming growth factor (TGF)-beta family type I receptor
implicated in a subset of human AVMs. Knockdown of alk1 caused a spectrum of morphologic, functional, and molecular defects
that resemble those seen in humans with AVMs. It was found that losartan, an angiotensin II receptor antagonist, attenuated
abnormal blood vessel morphology and systemic manifestations of high-output arteriovenous shunting in vivo. SMAD1
phosphorylation was signiﬁcantly decreased in alk1 morphants compared with uninjected organisms (0.189±0.0201,
0.429±0.0164, P¼0.0002). After treatment, morphant SMAD1 levels approached uninjected levels (0.326±0.0360, P¼0.0355) and
were signiﬁcantly higher than those seen in the morphant-control group (P¼0.0294). These data suggest that modulating the BMP
signaling pathway with losartan, a drug in widespread clinical use in humans as an antihypertensive, may have the potential to be
further evaluated as a therapeutic strategy for patients with AVMs.
Journal of Cerebral Blood Flow & Metabolism (2014) 34, 1688–1694; doi:10.1038/jcbfm.2014.134; published online 23 July 2014
Keywords: arteriovenous malformation; losartan; medical therapy; stroke; zebraﬁsh
INTRODUCTION
Arteriovenous malformations (AVMs) of the brain are vascular
anomalies of children and adults that carry a high risk of stroke.
1
Their primary pathologic phenotypic characteristic is a direct
communication between arteries and veins without an interven-
ing capillary bed. Treatment of these lesions is limited to surgery,
focused external beam radiation, and/or endovascular emboliza-
tion; no speciﬁc FDA (Federal Drug Administration)-approved
pharmacologic therapies currently exist. For unruptured cerebral
AVMs, a recent randomized trial of these interventional pro-
cedures versus conservative management (A Randomized Trial
of Unruptured Brain Arteriovenous Malformations, ‘ARUBA’—
ClinicalTrials.gov identiﬁer NCT00389181) was undertaken to
determine the best management paradigm. In 2013, the National
Institute of Neurological Disorders and Stroke halted rando-
mization and enrollment within the ARUBA trial, underscoring the
procedural risk associated with treatment of cerebral AVMs with
currently available modalities and the need for new treatments.
The process by which AVMs develop is poorly understood,
although aberrations in blood vessel formation and segregation
during embryonic development and adult life are thought to be
responsible. In development, the establishment of a vascular identity
(be it arterial or venous) initiates from molecular signals that result in
functional, and subsequently structural changes.
2,3 There are several
hierarchical signaling pathways that promote or inhibit divergent
endothelial cell fates, including hedgehog,
4 vascular endothelial
growth factor,
5,6 notch,
7,8 transforming growth factor (TGF)-beta,
9
and the ephrin ligand-receptor pathway,
10 among others. These
pathways have a complex interaction and are crucial regulators of
vascular assembly, differentiation, and boundary formation.
Despite a robust understanding of vasculogenesis and angio-
genesis, the mechanisms behind the formation of discrete AVMs
are not well known. These lesions occur either sporadically or
much more rarely, in the context of a hereditary syndrome. One
such syndrome in humans, hereditary hemorrhagic telangiectasia
type-2, is caused by a mutation in the gene encoding activin
receptor like kinase 1 (ALK1 or ACVRL1), a type I TGF-beta receptor
in the BMP signaling pathway.
11 This known mutation provides an
opportunity to study the pathogenic mechanisms of AVMs in
vertebrate models. The optical clarity of zebraﬁsh embryos with
ﬂuorescent vasculature, their ability to be genetically altered with
knockdown technology, and their ability to be treated with small
molecules permits the study of cerebral AVMs in vivo on an
unprecedented scale.
12 This zebraﬁsh model was utilized in
experiments with the goal of identifying a small molecule with
activity against cerebral AVM formation.
MATERIALS AND METHODS
The investigation was approved by the Massachusetts General Hospital
Institutional Review Board and conforms to the ‘Guide for the Care and Use
of Laboratory Animals’ published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
Morpholino Injection
A custom, alk1 splice-site blocking morpholino (50-ATCGGTTTCACTCACC
AACACACTC-30) was generated (Gene Tools, LLC, Philomath, OR, USA). This
1Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA and
2Cardiovascular Research Center, Massachusetts
General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA. Correspondence: Dr BP Walcott, Department of Neurological Surgery, Massachusetts General
Hospital, 55 Fruit Street, White Building Room 502, Boston, MA 02114, USA.
E-mail: walcott.brian@mgh.harvard.edu
Funding for this research was made in part by the Brain Aneurysm Foundation, the American Medical Association Seed Grant program, and the Congress of Neurological
Surgeons.
Received 3 May 2014; revised 2 June 2014; accepted 30 June 2014; published online 23 July 2014
Journal of Cerebral Blood Flow & Metabolism (2014) 34, 1688–1694
& 2014 ISCBFM All rights reserved 0271-678X/14
www.jcbfm.commorpholino has previously been shown to generate AVMs in zebraﬁsh.
13
Morpholino efﬁcacy was previously veriﬁed by PCR identiﬁcation of
splicing defects in the targeted genes. The morpholino was resuspended
in 1  Danieu’s solution and 2.5ng was injected into the cell bodies of
fertilized eggs from Tg(ﬂk1:EGFP) zebraﬁsh pair matings at the single-cell
stage. Arteriovenous malformations were generated in 498% of
organisms.
Zebraﬁsh Maintenance and Drug Exposure
Zebraﬁsh were raised in accordance with standard husbandry protocols.
(The age of embryos is indicated by the hours after fertilization and days
after fertilization for all experimental data shown.) Morpholino-injected
or -uninjected embryos were placed into a 96-well microtiter plate with
buffered embryo water (E3). The total volume of the embryos and the E3
was 100mL per well. These plates were then incubated at 281C in the dark.
All chemicals were then applied at 24h.p.f.; losartan was used at a
concentration of 20mmol/L or 100mmol/L (DMSO as a dilutant) and DMSO
was used as a control, always at a concentration of o1%. The drug
concentrations were determined based on preliminary experiments (dose
escalation trials not shown) to identify biologically active doses that did
not impair normal developmental milestones in the ﬁsh.
Morphometric Analysis
Embryos at 4d.p.f. were anesthetized by adding Tricaine (0.02% w/v) to E3
solution. They were then transferred to a petri dish, oriented in a sagittal
proﬁle, and examined under a Zeiss Examiner A1 stereomicroscope (Carl
Zeiss Microscopy, Thornwood, NY, USA) Images were captured and then
analyzed using ImageJ version 1.46 (NIH, Bethesda, MD, USA). A straight
line was generated from the center of the lens to the most posterior aspect
of the yolk sac. A separate straight line was generated from the posterior
aspect of the yolk sac to the tip of the tail. The angle between these lines
was automatically calculated, yielding a continuous variable that repre-
sented the systemic manifestations of the AVM on whole organism
morphology. It is suspected that paucity of ﬂow to the body impairs
normal developmental processes, particularly with respect to renal
organogenesis, resulting in organism curvature. Sixteen organisms were
measured for each group (uninjected, morphant-control, and morphant-
treatment).
Fluorescent Histology
JB-4 plastic resin was selected to examine the cranial vasculature given its
high level of tissue preservation, ﬂuorescence preservation, and cellular
resolution. In all, 4d.p.f. embryos were embedded, serially sectioned, and
visualized using a modiﬁcation of methods previously described.
14 The
embryos were ﬁxed in a 4% paraformaldehyde solution at 41C overnight.
They were then dehydrated in EtOH and inﬁltrated overnight. Embryos
were then transferred to molds where embedding solution was applied.
Before solidiﬁcation, organisms were oriented in the same direction,
parallel to the ﬂoor. Resin blocks were allowed to harden in the dark at 41C
to preserve ﬂuorescence. A glass microtome was used to section 8mmol/L
thick slices through the entire organism in the coronal plane. Samples
were transferred to glass slides, where Permaﬂuor aqueous mounting
medium (Thermo Scientiﬁc, Waltham, MA, USA) and a glass coverslip were
applied. Images at the level of the mid-eye (lens) were selected and the
diameter of the primordial hindbrain channels (left and right) were
measured using ImageJ version 1.46 (NIH, Bethesda, MD, USA). Twelve
organisms were measured for each group (uninjected, morphant-control,
and morphant-treatment).
Phosphorylated SMAD1 Enzyme-Linked Immunosorbent Assay
The InstantOne ELISA kit (eBioscience, San Diego, CA, USA) was used to
measure levels of phosphorylated SMAD1 (Ser463/465) in whole embryo
lysates. This kit is also predicted to detect the analogous phosphorylation
sites of SMAD5 and SMAD8. Using a modiﬁed protocol, six organisms per
well were lysed at 4dpf with a combination of cell lysis buffer and
mechanical homogenization. Lysate and phospho-SMAD1 (Ser463/465)
Figure 1. Experimental design and arteriovenous malformation (AVM) characteristics. (1) An alk1 splice-site blocking morpholino (2.5ng) was
injected into the cell bodies of fertilized eggs from Tg(ﬂk1:EGFP) zebraﬁsh pair matings at the single-cell stage. (2) The morpholino binds to
RNA, preventing translation. (3) AVMs were generated in 498% of organisms after injection. When compared with wild-type embryos, many
of the connections between the basal communicating artery and the primordial midbrain channel in the morphant are not present (white
arrows), analogous to the absence of an intervening capillary bed in the human condition. When a connection is present between the basal
communicating artery and the primordial midbrain channel, it is an abnormal ﬁstulous connection (red arrow). Zebraﬁsh images are two-
dimensional confocal projections of 72hours after fertilization Tg(ﬂk1:EGFP) embryos, dorsal views, anterior leftwards.
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the InstantOne assay plate. After 1hour of incubation, wells were washed
and a detection solution was applied. Absorbance was measured at
450nm. Positive control cell lysate and negative control (cell lysis buffer)
conﬁrmed antibody efﬁcacy. Twenty-four organisms were measured for
each group (uninjected, morphant-control, and morphant-treatment).
Experiments were repeated in triplicate.
Statistical Methods
To compare continuous variables, a two-tailed Student’s t-test was used
(GraphPad, La Jolla, CA, USA). Signiﬁcance was predeﬁned at Po0.05.
Unless otherwise stated, data are expressed as mean±s.e.m.
RESULTS
Morpholino Knockdown of alk1 Results in Cerebral Arteriovenous
Malformation Formation in Zebraﬁsh
The genetic basis for AVMs is not well understood, making
evaluation of targeted therapies challenging. However, mutations
in alk1 are associated with the development of hereditary
hemorrhagic telangiectasia type-2 (OMIM 601284), a syndrome
typiﬁed by the development of AVMs in numerous locations.
Injection of the alk1 morpholino in the cell body at the single-cell
zebraﬁsh embryo (Figure 1) resulted in the subsequent develop-
ment of AVMs in 498% of organisms (Figure 2). Abnormal
shunting of circulation was visible by 24h.p.f., with a prominent
circuit of cranial circulation. There was a paucity of circulation
caudal to the heart, despite the development of normal vascular
architecture. By 3 to 4d.p.f., alk1 knockdown zebraﬁsh began to
develop objective signs of the sequelae resulting from high-
output heart failure including pericardial edema, cerebral edema,
and edema surrounding the remaining yolk sac.
Compound Selection
Losartan was selected for testing in the zebraﬁsh AVM model
given its demonstrated biologic activity seen in various aspects of
TGF-beta superfamily pathways in humans. It is a widely used,
orally administered FDA-approved medication for hypertension
with an excellent safety proﬁle.
15 Although its primary target is the
angiotensin II type 1 receptor (AT1), it is also known to indirectly
attenuate canonical TGF-beta signaling in the vasculature.
16
Additionally, its vascular modifying effects are also the current
focus of a phase 3 clinical trial (ClinicalTrials.gov identiﬁer:
NCT00763893; Efﬁcacy of Losartan on Aortic Dilatation in
Patients with Marfan Syndrome).
Treatment with Losartan Attenuates Abnormal Vasculature in
Zebraﬁsh Cerebral Arteriovenous Malformation Morphants
In alk morphants, treatment with losartan partially rescued the
AVM phenotype. Measurements of the primordial hindbrain channel
were signiﬁcantly different between uninjected and morphant-
control groups (0.0108±0.00198mm
2, 0.0449±0.00269, Po0.0001),
whereas measurements from losartan-treated morphants (0.0103±
0.00101) were not signiﬁcantly different from uninjected organ-
isms (P¼0.8574) (Figure 3). Losartan treatment of wild-type
organisms did not alter normal vascular development (not shown).
Treatment with Losartan Attenuates the Systemic Organism-Level
Phenotype in Zebraﬁsh Cerebral Arteriovenous Malformation
Morphants
In addition to vessel architecture, the hemodynamic properties of
experimental organisms were measured, using whole organism
morphometric characteristics as a surrogate. In uninjected organisms
the cranial–caudal angle was measured to be 176.0±0.6488
Figure 2. Epiﬂuorescence and confocal microscopy of alk1 morphants shows dilation of cranial vessels. (A) Morphant-control and (C)
uninjected zebraﬁsh at 4dpf with endothelial expression of enhanced green ﬂuorescent protein show that primordial hindbrain channels
(outlined in white dots) are dilated in the morphant-control group compared with uninjected organisms. This channel is one of the main
vessels in the cranial arteriovenous shunting circuit. Inset boxes show representative two-dimensional confocal projections of (B) morphant-
control and (D) morphant-treatment zebraﬁsh, where the outlined vessel (primordial hindbrain channel) is identiﬁed by white arrows (dorsal
views, anterior leftwards). The diameter of the primordial hindbrain channel is markedly reduced in the group treated with losartan (D).
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control group 97.50±4.987, Po0.0001 reﬂecting a dorsal
curvature of the tail (Figure 4) Treatment with losartan in the
morphant-treatment group rescued this curvature, increasing the
angle to 160±3.38, Po0.0001.
Functionally, hemodynamics were directly observed between
the three experimental groups using light microscopy. The
qualitative absence (or near absence) of blood ﬂow in the body
and tail region of any organism was identiﬁed corresponding to
the alk1 phenotype. In uninjected organisms (n¼47), 100%
showed robust body and tail circulation (Supplementary Video 1).
In the morphant-control group (n¼19), 15.8% were observed to
have tail ﬂow, compared with the morphant-treatment groups
(20 mmol/L losartan, 25.9% (n¼27); 100mmol/L losartan, 40.0%
(n¼25)) (Supplementary Videos 2–4).
Treatment with Losartan Partially Normalizes Phospho-SMAD1
Levels Caused by alk1 Knockdown
It was hypothesized that the ability of losartan to rescue the
vascular and morphologic effects of alk1 knockdown was due to
an increase in BMP pathway signaling. To test this possibility,
whole embryo lysate at 4d.p.f. was analyzed via enzyme-linked
immunosorbent assay for expression of phosphorylated levels
of SMAD1. SMAD1 phosphorylation was signiﬁcantly decreased
in alk1 morphants compared with uninjected organisms
(0.189±0.0201, 0.429±0.0164, P¼0.0002). After treatment with
losartan, morphant SMAD1 levels approached uninjected levels
(0.326±0.0360, P¼0.0355) and were signiﬁcantly higher than
those seen in the morphant-control group (P¼0.0294) (Figure 4).
Therefore, losartan’s ability to attenuate the alk1 knockdown
phenotype may be associated with its ability to increase SMAD1
phosphorylation.
DISCUSSION
Currently, there are no FDA-approved pharmacologic treatments
for cerebral AVMs in humans. One attractive approach for
developing such therapies is repurposing of existing drugs, which
could theoretically reduce the developmental and regulatory
burden required for new drug approval. Therefore, an AVM model
that allows rapid testing of drug candidates could be useful for
identifying existing drugs with activity against AVMs.
Several mammalian models of cerebral AVMs exist, but are
limited in their applicability for drug discovery. For example,
cerebral AVMs have been created in swine, but this method
requires a combination of surgical intervention and hemodynamic
response to generate a lesion that mimics the human condition.
17
Additionally, mice have been used as model organisms, although
they require angiogenic stimulation with vascular endothelial
growth factor, in addition to genetic manipulation of alk1 to
generate lesions.
18 This confounds the interpretation of treat-
ments such as vascular endothelial growth factor antagonists,
particularly since vascular endothelial growth factor stimulation is
necessary to generate the model.
19 Zebraﬁsh are an attractive
model in that their vasculature is visualized easily with ﬂuorescent
proteins and their entire cranial circulation can be observed
in vivo.
By using morpholino technology, we were able to manipulate
the gene expression of alk1, creating zebraﬁsh with cerebral
AVMs.
20 This established zebraﬁsh AVM model recapitulates the
human disease with a high level of ﬁdelity.
13,20 The appearance of
abnormal anomalous vessels connecting the arterial and venous
circulation is sine qua non for the condition in humans.
21 Beyond
the appearance of the abnormal blood vessels, alk1 knockdown
zebraﬁsh also show characteristic systemic manifestations of the
accompanying pathophysiologic hemodynamic response that is
Figure 3. Histologic assessment of cerebral vasculature shows dilated cranial blood vessels in an arteriovenous malformation (AVM) model. 4-
dpf zebraﬁsh were embedded in JB-4 resin, serially sectioned, and visualized at the level of the mid-eye in the coronal plane. Measurements of
the primordial hindbrain channels were signiﬁcantly smaller in the (A) uninjected organisms compared with the (B) morphant-control group
(Po0.0001). (C, D) Morphant-treatment group measurements (0.0103±0.00101mm
2) were not signiﬁcantly different from uninjected
organisms (P¼0.8574), consistent with a rescue phenomenon of the vascular phenotype.
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pediatric population.
22,23
Targeted evaluation of losartan, an FDA-approved antihyper-
tensive medication in widespread clinical use, resulted in a
modest attenuation of the zebraﬁsh AVM phenotype. This could
be seen in a trend toward normalization of the abnormal cranial
vasculature and hemodynamic pertubations seen with the
experimental model. Furthermore, the loss of SMAD1 phosphor-
ylation associated with alk1 knockdown was rescued by losartan
treatment.
The effects of losartan on zebraﬁsh AVMs are not the ﬁrst
example of its beneﬁcial effects on a congenital vascular condition.
Losartan has been shown to prevent aortic aneurysm develop-
ment
24 and progression
25 in a mouse model of Marfan syndrome.
On the basis of these and other data, several active clinical trials
are now investigating the efﬁcacy of losartan in treating aortic
aneurysms in humans. The central hypothesis underlying these
trials is that losartan antagonizes TGF-beta signaling,
26,27 likely by
inhibition of the AT1 receptor or other pathways independent
of a TGF-beta receptor itself.
16 However, less is known about
the inﬂuence of AT1 on the opposing BMP signaling pathway
(the pathway directly inﬂuenced by mutations in alk1).
It was suspected that the molecular mechanism underlying the
rescue mechanism of losartan treatment is related to restoration
of BMP signaling. Conceptually, the TGF-beta and BMP pathways
balance each other through opposing mechanisms to regulate
gene expression (Figure 5).
28,29 Alk1 activation normally induces
phosphorylation of SMAD1/5/8,
30 congruent with the ﬁnding
that phosphorylated levels of SMAD1 were decreased in alk1
knockdown organisms. Treatment with losartan increased the
levels of phosphorylated SMAD1 in knockdown organisms,
suggesting that phosphorylation of SMAD1/5/8 is necessary for
transcription of speciﬁc target genes needed to maintain the
differentiation between arterial and venous structures.
31,32 It is
well known from preclinical
33,34 and human
35 studies that systemic
antagonism of TGF-beta signaling by losartan is possible. It is also
known that levels of phosphorylated SMAD 2/3 in the TGF-beta
pathway are decreased by losartan.
33,34 The presented data
support an additional possible mechanism of action for losartan in
regulating vascular development and homeostasis: activation of
the BMP signaling pathway via AT1 inhibition. Alternative explana-
tions for our ﬁndings resulting from losartan administration center
around the promiscuous nature of ALK1 utilization. For example,
in endothelial cells, ALK1 can partner with TGF-beta II receptors
(RII) and support TGF-beta mediated SMAD1/5 phosphorylation.
This same receptor complex can inhibit TGF-beta mediated
SMAD2/3 phosphorylation via RII/ALK5 complex.
36 Thus, it is also
plausible that loss of ALK1 signaling leads to excessive TGF-beta
mediated Smad2/3 phosphorylation in the morphant group.
Further work to characterize the molecular landscape in human
AVM tissue is necessary for a more complete understanding of the
pathogenic mechanisms involved.
Figure 4. Morphometric and suppression of canonical transforming growth factor (TGF)-beta signaling changes in alk1 knockdown zebraﬁsh
are corrected with losartan treatment. (A) 4dpf zebraﬁsh were analyzed for whole organism morphometric changes (the cranial–caudal angle)
as a surrogate for pertubations in hemodynamics between groups. (B) In uninjected organisms, the cranial–caudal angle was measured to be
176.0±0.6488 degrees, (C) whereas it was signiﬁcantly more acute in the morphant-control group 97.50±4.987, Po0.0001. Morphant
organisms frequently showed systemic evidence of high-output cardiac failure, including pericardial edema (star). (D, E) Treatment with
losartan increased the cranial–caudal angle to 160±3.38, which was greater than the morphant-control group, Po0.0001. (F) The InstantOne
ELISA kit (eBioscience) was used to measure levels of phosphorylated SMAD1 (Ser463/465) in whole embryo lysates. Absorbance in morphant-
control group was signiﬁcantly decreased compared with uninjected organisms (0.189±0.0201, 0.429±0.0164, P¼0.0002). After treatment
with losartan, morphant levels approached uninjected levels (0.326±0.0360, P¼0.0355) and was signiﬁcantly higher than the morphant-
control group (P¼0.0294).
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how broadly might it be effective for treating AVMs? Mendelian
inheritance of alk1 mutations accounts for only a small percentage
of all AVMs.
37–39 Nevertheless, evidence exists that single-
nucleotide polymorphisms in alk1 occur in many sporadic
occurring AVMs.
40,41 Therefore, these ﬁndings may be applicable
to AVMs that occur in the sporadic setting, as well as in cases of
Mendelian alk1 mutation. Ultimately, the efﬁcacy of any treatment
must also be evaluated for the ability to cause regression of well-
established lesions, which is the clinical condition seen in humans.
Given losartan’s ease of administration, tolerability, and favorable
safety proﬁle, future human studies of losartan may be warranted.
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